H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $5 from $10 and keeps a Buy rating on the shares following the Q4 report. The firm removed revenue projections for both lunresertib and camonsertib after the company announced that it has deprioritized these assets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX: